RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases characterized by pulmonary inflammation, is pleased to announce ...
RSBT-001 was evaluated in three separate, inducible experiments designed to test the ability of RSBT-001 to attenuate inflammation and fibrosis in human precision cut lung slices (PCLuS).
First-in-class, steroid-free compound reduced inflammatory and fibrotic biomarkers in human lung tissue furthering support as a new advancement in the treatment of deadly lung diseases CUMBERLAND, Md.
(MENAFN- GlobeNewsWire - Nasdaq) First-in-class, steroid-free compound reduced inflammatory and fibrotic biomarkers in human lung tissue furthering support as a new advancement in the treatment of ...